Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Sales (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Sales for 4 consecutive years, with 0.37% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 214.0% to 0.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.26%, a 479.0% increase, with the full-year FY2025 number at 1.26%, up 479.0% from a year prior.
  • Return on Sales was 0.37% for Q4 2025 at Phathom Pharmaceuticals, up from 0.61% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 18.41% in Q3 2023 to a low of 116.65% in Q4 2023.
  • A 4-year average of 7.21% and a median of 0.49% in 2025 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -12237bps in 2023, then soared 11414bps in 2024.
  • Phathom Pharmaceuticals' Return on Sales stood at 5.72% in 2022, then crashed by -2138bps to 116.65% in 2023, then skyrocketed by 98bps to 2.51% in 2024, then soared by 85bps to 0.37% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Return on Sales are 0.37% (Q4 2025), 0.61% (Q3 2025), and 1.92% (Q2 2025).